SGCB and chronic thromboembolic pulmonary hypertension: For example, riociguat, the first in class sGC stimulator, was approved for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in 2013, and it has been shown pre-clinically to enhance memory performance in mice via peripheral mechanisms [36].